Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 2
1977 1
1979 1
1980 1
1981 3
1982 2
1983 2
1984 3
1985 4
1986 4
1987 2
1988 1
1989 6
1990 3
1991 6
1992 5
1993 17
1994 3
1995 6
1996 3
1997 5
1998 7
1999 8
2000 7
2001 20
2002 13
2003 17
2004 10
2005 12
2006 18
2007 16
2008 1
2009 6
2010 7
2011 3
2012 3
2013 3
2014 9
2015 6
2016 11
2017 20
2018 15
2019 12
2020 13
2021 19
2022 15
2023 12
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

339 results

Results by year

Filters applied: . Clear all
Page 1
Predictors and consequences of intellectual humility.
Porter T, Elnakouri A, Meyers EA, Shibayama T, Jayawickreme E, Grossmann I. Porter T, et al. Among authors: shibayama t. Nat Rev Psychol. 2022;1(9):524-536. doi: 10.1038/s44159-022-00081-9. Epub 2022 Jun 27. Nat Rev Psychol. 2022. PMID: 35789951 Free PMC article. Review.
Giant multilocular prostatic cystadenoma.
Nakamura Y, Shida D, Shibayama T, Yoshida A, Matsui Y, Shinoda Y, Iwata S, Kanemitsu Y. Nakamura Y, et al. Among authors: shibayama t. World J Surg Oncol. 2019 Feb 26;17(1):42. doi: 10.1186/s12957-019-1579-7. World J Surg Oncol. 2019. PMID: 30808350 Free PMC article.
Immuno-genomic analysis reveals eosinophilic feature and favorable prognosis of female non-smoking esophageal squamous cell carcinomas.
Okawa Y, Sasagawa S, Kato H, Johnson TA, Nagaoka K, Kobayashi Y, Hayashi A, Shibayama T, Maejima K, Tanaka H, Miyano S, Shibahara J, Nishizuka S, Hirano S, Seto Y, Iwaya T, Kakimi K, Yasuda T, Nakagawa H. Okawa Y, et al. Among authors: shibayama t. Cancer Lett. 2024 Jan 28;581:216499. doi: 10.1016/j.canlet.2023.216499. Epub 2023 Nov 25. Cancer Lett. 2024. PMID: 38013050 Free article.
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis.
Tanaka H, Tanzawa S, Misumi T, Makiguchi T, Inaba M, Honda T, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Fujimoto N, Fukuda Y, Yasugi M, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Shiraishi K, Matsutani N, Seki N. Tanaka H, et al. Among authors: shibayama t. Ther Adv Med Oncol. 2022 Dec 18;14:17588359221142786. doi: 10.1177/17588359221142786. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36570411 Free PMC article.
A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations.
Ninomiya T, Ishikawa N, Kozuki T, Kuyama S, Inoue K, Yokoyama T, Kanaji N, Yasugi M, Shibayama T, Aoe K, Ochi N, Fujitaka K, Kodani M, Ueda Y, Watanabe K, Bessho A, Sugimoto K, Oze I, Hotta K, Kiura K. Ninomiya T, et al. Among authors: shibayama t. Lung Cancer. 2023 Oct;184:107349. doi: 10.1016/j.lungcan.2023.107349. Epub 2023 Aug 19. Lung Cancer. 2023. PMID: 37651927 Clinical Trial.
Reply to "Benralizumab as a First-line Treatment for ABPA: Is It Really Indicated?".
Matsuura H, Fujiwara K, Omori H, Onishi K, Kuribayashi T, Mitsumune S, Takigawa Y, Kudo K, Sato A, Sato K, Shibayama T. Matsuura H, et al. Among authors: shibayama t. Intern Med. 2021 Aug 1;60(15):2521. doi: 10.2169/internalmedicine.6952-20. Epub 2021 Feb 15. Intern Med. 2021. PMID: 33583909 Free PMC article. No abstract available.
Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study.
Kogure Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Saka H, Ebi N, Inoue A, Kurata T, Fujita Y, Nishii Y, Itani H, Endo T, Saito AM, Shibayama T, Yamamoto N, Gemma A. Kogure Y, et al. Among authors: shibayama t. JTO Clin Res Rep. 2023 Apr 6;4(6):100514. doi: 10.1016/j.jtocrr.2023.100514. eCollection 2023 Jun. JTO Clin Res Rep. 2023. PMID: 37304652 Free PMC article.
339 results